Earnings Call Excerpt
Millennium Pharmaceuticals Inc. (MLNM)
Q4 2005 Earnings Conference Call
January 26th 2006, 8:30 PM.
Executives:
Dr. Deborah Dunsire, President and Chief Executive Officer
Marsha Fanucci, Chief Financial Officer & Sr. VP Corporate Strategy
Dr. Robert Tepper, President of Research and Development
Dr. Nancy Simonian, Sr. VP Clinical Research & Regulatory and Medical Affairs
Lisa Adler, VP Global Corporate Affairs
Analysts:
John Wilson, Robert W. Baird
David Witzke, Banc Of America Securities
Philip Nadeau, SG Cowen
Rachel McMinn, Piper Jaffray
Chris Metropolis, J.P. Morgan
Maneesh Jain, Thomas Weisel Partners
Presentation
Operator
Ladies and Gentlemen, thank you for holding and welcome to the Millennium Pharmaceuticals Conference Call. At this time all participants are in a listen-only mode. There will be a Question and Answer session to follow. Please be advised that this call is being recorded at the company’s request. At this time, I would like to introduce your host for today’s call, Mr. Kyle Kuvalanka, Director, Investor and Corporate Communications at Millennium Pharmaceuticals. Please go ahead sir.
Kyle Kuvalanka, Director, Investor and Corporate Communications
Good morning everyone and welcome to Millennium’s Conference call to discuss the financial results for 2005. With me today are Dr. Deborah Dunsire, our President and Chief Executive Officer; Marsha Fanucci, Chief Financial Officer and Senior Vice-President of Corporate Strategy; Dr. Robert Tepper, President of Research and Development; Dr. Nancy Simonian, Senior Vice President of Clinical Research and Regulatory and Medical Affairs; Lisa Adler, Vice-President of Global Corporate Affairs.
Our agenda for this morning is as follows: Marsha will open with the highlights of our financial results for the year, Bob will provide an update on research and development activities, Deborah will then ramp up our prepared comments. We will then take your questions. Before we begin, let me remind you we will be making forward-looking statement, when we discuss our growth signs, products and cost effects, a point of reference is how we as a company think, expect or believe the future will look based on information as we know it today. No one can predict the future, and there are risks that could cause the company’s actual results could differ materially from these statements. You can review a list and description of these risks in the reports we filed with the SEC.
During this call we will be referring to non-GAAP net loss, non-GAAP net income, and non-GAAP profitability. These financial measures are not prepared in accordance with Generally Accepted Accounting Principles. Description of the differences between these non-GAAP financial measures and the most directly comparable GAAP measures is included in the press release we issued this morning. A discussion of why we believe these measures are useful for investors and of the additional purposes for which management uses these measures is included in the Form 8-K we furnished to the SEC this morning. The press release and the Form 8-K are available on the Investor section on our website. Let me now turn the call over the Marsha.
- To read the full transcript on Seeking Alpha, click here »
